neurovascular
(5)
David Stoffel
David Stoffel is the Chief Business Officer of RapidAI, the clinical-AI company whose stroke-imaging algorithms helped rewrite the rules of how strokes get treated. A medical doctor who chose boardrooms over bedsides, he has spent more than two decades turning ambitious medical technologies into standards of care - from the da Vinci surgical robot at Intuitive Surgical to mobile cardiac telemetry at iRhythm and point-of-care EEG at Ceribell. At RapidAI he runs the commercial engine: marketing, clinical affairs, education, customer success, corporate development, and finance.
Eduardo Fonseca
Eduardo Fonseca is the CEO of XCath, a Houston- and Pangyo-based medtech company building endovascular robotic systems and steerable guidewires to treat stroke and other cerebrovascular conditions. A former Panamanian ambassador to the UAE and Saudi Arabia turned investor and operator, he joined the XCath board in 2019 and took the helm in 2023, also serving as interim CEO of sister company EndoQuest Robotics. Under his leadership XCath has logged a string of world firsts, including the first public remote mechanical thrombectomy demonstration and, in 2026, the world's first remote robotic intervention in a stroke patient.
Sungwoo Min
Sungwoo Min is the founder and CEO of Nventric, Inc., an Arcadia, California medical device company that designs, develops, and contract-manufactures vascular devices for the neurovascular, electrophysiology, and coronary markets. A Stanford-trained mechanical engineer who cut his teeth on R&D and marketing at Abbott Vascular and later led R&D programs at Johnson & Johnson, he started Nventric in 2019 to build the kind of life-saving catheters, stents, and thrombectomy systems he used to ship at the giants - this time end to end, ISO 13485 certified, with operations in the US and South Korea. He is a named inventor on multiple US patents for mechanical thrombectomy devices.
Karim Karti
Karim Karti is the CEO of RapidAI, a deep clinical AI company whose platform is used in 2,500+ hospitals across 100+ countries for stroke, vascular, and radiology workflows. He brings 22+ years from GE Healthcare — including running its $9B imaging division — and a stint as COO of iRhythm, where he doubled revenues to $210M in 18 months. Trained as an engineer in France and a former P&G brand manager, he now leads one of the most clinically validated AI platforms in medicine, backed by 700+ published studies and 10+ million scans processed.
Adam Elsesser
Adam Elsesser is the co-founder, Chairman and CEO of Penumbra, the Alameda-based medical device company that pioneered aspiration thrombectomy for stroke. A former real estate lawyer turned operator, he has run Penumbra since 2004 and, in January 2026, agreed to sell it to Boston Scientific for roughly $14.5 billion.